scholarly journals Corrigendum to “Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles” [Eur J Cancer 70 (2017) 62–74]

2017 ◽  
Vol 83 ◽  
pp. 335
Author(s):  
Jolene Read ◽  
Alistair Ingram ◽  
Hassan A. Al Saleh ◽  
Khrystyna Platko ◽  
Kathleen Gabriel ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Androgen Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Extracellular Vesicles ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Exogenous Epidermal Growth Factor

scholarly journals Senescent cholangiocytes release extracellular vesicles that alter target cell phenotype via the epidermal growth factor receptor

2020 ◽  
Vol 40 (10) ◽  
pp. 2455-2468 ◽  
Author(s):  
Mohammed S. Al Suraih ◽  
Christy E. Trussoni ◽  
Patrick L. Splinter ◽  
Nicholas F. LaRusso ◽  
Steven P. O’Hara
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Extracellular Vesicles ◽  
Target Cell ◽  
Growth Factor Receptor ◽  
Cell Phenotype ◽  
Epidermal Growth

Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells

2011 ◽  
Vol 18 (4) ◽  
pp. 451-464 ◽  
Author(s):  
Yichun Zheng ◽  
Koji Izumi ◽  
Jorge L Yao ◽  
Hiroshi Miyamoto
Keyword(s):  
Bladder Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Androgen Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tumor Progression ◽  
Cancer Cells ◽  
Growth Factor Receptor ◽  
Bladder Cancer Cells ◽  
Epidermal Growth

Androgen receptor (AR) signals play important roles in bladder carcinogenesis and tumor progression. Activation of the epidermal growth factor receptor (EGFR) family, including EGFR and ERBB2, leads to bladder cancer cell growth and correlates with poor patients' prognosis. However, cross talk between AR and EGFR/ERBB2 pathways in bladder cancer remains poorly understood. In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels, and an anti-androgen hydroxyflutamide antagonized the effect of DHT. The necessity of AR was confirmed by silencing the receptor, using short hairpin RNA (shRNA), in UMUC3 cells, as well as by expressing the receptor in AR-negative 5637 cells. Of note were much higher basal levels of EGFR and ERBB2 in UMUC3-control-shRNA than in UMUC3-AR-shRNA and those of EGFR in 5637-AR than in 5637-V. DHT additionally upregulated the levels of phosphorylation of EGFR (pEGFR) and its downstream proteins AKT (pAKT) and ERK1/2 (pERK), induced by EGF treatment, in AR-positive cells. Immunohistochemistry on cystectomy specimens showed strong associations between expressions of AR and EGFR (P=0.0136), pEGFR (P=0.0041), ERBB2 (P=0.0331), or pERK (P=0.0274), but not of pAKT (P=0.5555). The Kaplan–Meier and log-rank tests further revealed that positivity of AR (P=0.0005), EGFR (P=0.2425), pEGFR (P=0.1579), ERBB2 (P=0.2997), or pERK (P=0.1270) and negativity of pAKT (P=0.0483) were associated with tumor progression. Our results indicate that AR activation upregulates the expression of EGFR and ERBB2 in bladder cancer cells. AR signals may thus contribute to the progression of bladder cancer via regulation of the EGFR/ERBB2 pathways.

scholarly journals Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines

2007 ◽  
Vol 38 (1) ◽  
pp. 51-66 ◽  
Author(s):  
Lorella Bonaccorsi ◽  
Daniele Nosi ◽  
Monica Muratori ◽  
Lucia Formigli ◽  
Gianni Forti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Androgen Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cell Lines ◽  
Growth Factor Receptor ◽  
Epidermal Growth

Although androgens and the androgen receptor (AR) are involved in tumorigenesis of prostate cancer (PC) in initial phases, less clear is the role played in advanced androgen-independent (AI) stages of the disease. Several recent reports indicated that re-expression of AR in PC-derived cell lines determines a less aggressive phenotype of the cells. We have previously demonstrated that re-expression of AR decreases the invasion ability of PC3 cells in vitro by affecting signalling and internalization processes of epidermal growth factor receptor (EGFR). Here, we show that reduced EGFR internalization is also a characteristic of AR positive PC cell lines LNCaP and 22Rv1. Reduced internalization in PC3-AR cells is associated to a defective interaction between the EGFR and two adaptor proteins which mediate the endocytotic process, Grb2 and c-Cbl. As a consequence of such reduced interaction, ubiquitination of the receptor, which is mainly mediated by c-Cbl, is also altered. In addition, we show that internalized EGFR co-localizes with early endosome antigen-1, a marker of clathrin-mediated endocytosis, in PC3-Neo cells but not in AR positive cell lines. Conversely, EGFR maintains co-localization with caveolin-1 after EGF stimulation in PC3-AR cells. These data suggest that expression of AR affects clathrin-mediated endocytosis pathway of EGFR, which, according to recent findings, plays an essential role in the completeness of signalling of the receptor. Taken together, these data emphasize the role of AR in the regulation of EGFR endocytotic trafficking and active signalling in PC cells. In view of the role of EGFR signalling in invasion of carcinoma cells, our data may explain the lower invasive phenotype observed in AR-positive cell lines.

Sign in / Sign up

Export Citation Format

Share Document